Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives insight into how his practice will handle the influx of at least 7 adalimumab biosimilars referencing Humira that are expected to enter the market in 2023.
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, gives insight into how his practice will handle the influx of at least 7 adalimumab biosimilars referencing Humira that are expected to enter the market in 2023.
Transcript
Do you have an idea of how your health system will address the large number of adalimumab biosimilars that are going to enter the market in the coming year?
There's a lot coming to market. And I think we're excited about it. We want to be an early adopter of biosimilar use. I think we want to be thoughtful though. So, we'll keep engaging our providers that already have familiarity with biosimilars within the rheumatology and GI [gastrointestinal] space and get their feedback.
But at the same time, we can't stop every single one of the therapies. We want to make sure we're making the right ones available to our patients. We're going to work with our payer colleagues to figure out which ones should we consider adding the formulary but at the end of the day, each different type of product that we stock is a cash and cash equivalent. We want to be good stewards of our organization's money, choose the best therapy that will provide the best outcomes for our patients, have good payer coverage and meet our providers, but we will probably move quickly and really leverage that to reduce our cost of care.
HMO and EPO Insurance Plans More Likely to Promote Use of Biosimilars
November 21st 2023Health plan type highly influences the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More